The incidence of dementia in Parkinson’s Disease (PD) is very high. Approximately a quarter of the PD patients develop dementia of the Alzheimer’s type simply due to the overlap of these two age related degenerative disorders.

Indus is developing an interesting candidate that targets the SIRT 2 inhibitions for this class of diseases.